RxDoctor Payments Data

Jamie Stevenson

Psychiatric/Mental Health · Eugene, ORNPI 1174757355

Payments from drug & device makers

$1,116in general payments, 2019–2025

Across 36 payments — averaging $31.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$346
  • E.r. Squibb & Sons, L.L.C.$207
  • Otsuka America Pharmaceutical, Inc.$120
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$115
  • AbbVie$114
  • Teva Pharmaceuticals USA, Inc.$77
  • plus $137 from 5 others

What the payments were for

  • Food & beverage$1,08998%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,116 in reported general payments places this provider in the 85th percentile of 540 psychiatric/mental health providers in Oregon.

See all psychiatric/mental health providers in Oregon

Medicare billing

Part B allowed, 2024
$8,743
Medicare patients
12
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate94$251,230
Abilify MaintenaAripiprazole22$66,623
Clozapine102$6,362
Aripiprazole66$4,950
Lurasidone Hcl71$4,434
Divalproex Sodium ErDivalproex Sodium63$3,979
Quetiapine Fumarate187$3,577
Naltrexone Hcl41$2,261
Olanzapine168$2,074
Ziprasidone Hcl21$1,978
Paliperidone ErPaliperidone19$1,949
Haloperidol70$1,675
Prazosin Hcl54$1,373
Risperidone72$1,293
Quetiapine Fumarate ErQuetiapine Fumarate37$1,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$16$251,23094 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$120$66,62322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 540 psychiatric/mental health providers in Oregon.

Other psychiatric/mental health in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →